Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study

BMJ Open

Volumn 4, Issue 12, 2014, Pages

  Lee, Meng ^a   Wu, Yi Ling ^a   Saver, Jeffrey L ^b   Lee, Hsuei Chen ^c   Lee, Jiann Der ^a   Chang, Ku Chou ^a   Wu, Chih Ying ^a   Lee, Tsong Hai ^a   Wang, Hui Hsuan ^d   Rao, Neal M ^b   Ovbiagele, Bruce ^e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; HOSPITALIZATION; INCIDENCE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE; TAIWAN; TRENDS;

AGED; ASPIRIN; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84920514075     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006672     Document Type: Article

References (23)

1. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003;41:966-8.
2. Hennekens CH, Schror K, Weisman S, et al. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004;110:1706-8.
3. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley white lecture 1995. Circulation 1996;94:2013-20.
4. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
5. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006;186:240-59.
6. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66.
7. Lee M, Ovbiagele B. Vascular events after stroke: Terutroban fails to perform. Lancet 2011;377:1980-2.
8. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76.
9. Cheng CL, Kao YH, Lin SJ, et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.
10. Goldstein LB, Samsa GP, Matchar DB, et al. Charlson index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35:1941-5.
11. Wong MC, Tam WW, Cheung CS, et al. Drug adherence and the incidence of coronary heart disease - and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study. Int J Cardiol 2013;168:928-33.
12. Garcia Rodriguez LA, Cea Soriano L, Hill C, et al. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011;76:740-6.
13. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-14.
14. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006;367:1665-73.
15. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
16. Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost 2005;3:2649-55.
17. Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual - versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013;159:463-70.
18. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
19. Cote R, Zhang Y, Hart RG, et al. ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology 2014;82:382-9.
20. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 2006;1:158-9.
21. Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-97.
22. Saxena A, Balaramnavar VM, Hohlfeld T, et al. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 2013;721:215-24.
23. Ali LK, Saver JL. The ischemic stroke patient who worsens: New assessment and management approaches. Rev Neurol Dis 2007;4:85-91.